Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Allostim |
| Synonyms | |
| Therapy Description |
Allostim is a preparation of allogeneic CD4-positive Th1-like T-cells bound to microparticles coated with anti-CD3 and anti-CD28 antibodies, which potentially induces antitumor immune response (NCI Thesaurus, J Clin Oncol 2025 43:4_suppl, TPS318). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Allostim | Allostim is a preparation of allogeneic CD4-positive Th1-like T-cells bound to microparticles coated with anti-CD3 and anti-CD28 antibodies, which potentially induces antitumor immune response (NCI Thesaurus, J Clin Oncol 2025 43:4_suppl, TPS318). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04444622 | Phase II | Allostim | Immunotherapy for Third Line Metastatic Colorectal Cancer (STIMVAX) | Completed | USA | 0 |